Excimer Laser With Topical Agents in Psoriasis Vulgaris

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-10-30

Study Completion Date

2023-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Psoriasis is a chronic, immune-mediated disease that affects approximately 2% of the population. The development and exacerbation of psoriasis involve an interaction between multiple genetic and environmental risk factors.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Acitretin or Tazarotene Gel and Excimer Laser for Treatment of Psoriasis

NCT01094717

Psoriasis

TERMINATED NA

Addition of Excimer Laser to Treatment With Acitretin Tablets for Psoriasis of the Palms and Soles

NCT02181790

Psoriasis, Skin or Nails

TERMINATED PHASE4

Excimer Laser Phototherapy Outcomes in the Treatment of Psoriasis

NCT02294981

Psoriasis

TERMINATED NA

Efficacy of Combined Fractional Carbon Dioxide Laser and Topical Tazarotene in the Treatment of Psoriatic Nail Disease

NCT03263624

Nail Psoriasis

UNKNOWN PHASE4

Topical Methotrexate Microemulsion in the Treatment of Plaque Psoriasis

NCT04971239

Psoriasis Methotrexate

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Psoriasis presents as well-circumscribed, erythematous plaques with an overlying silvery white scales. It has an effect on various aspects of life including mental health, productivity and relationships.

Topical therapies as corticosteroids and vitamin D3 analogs are first-line treatments for mild plaque psoriasis; which involves less than 3% of the body surface area (BSA). Moderate-to-severe plaque psoriasis is usually managed with phototherapy, systemic or biologic therapies .

The American Academy of Dermatology gives a strength recommendation for the use of combination therapies for treatment of psoriasis with superior efficacy to monotherapy .

The 308-nm excimer laser has been widely used for many dermatological diseases. In psoriasis, it shows an efficacy in the treatment of localised plaques especially on the knees and elbows.

It is indicated in moderate to severe psoriasis that affects \<10% of the body surface. Areas such as nose, ears and palpebral region can be easily accessed using the laser. It induces lymphocytic apoptosis and decreases the proliferation rate of keratinocytes . There are multiple protocols that evaluate the clinical response to Excimer laser; the induration protocol, the minimal erythema dose and the minimal blistering dose.

The induration protocol compared with the others, allows to modify the dose with treatment. With this protocol, plaques achieved Psoriasis area and severity index (PASI-75) after 10 treatments .

Tazarotene (TAZ) is a topical retinoid with retinoic acid receptor β / γ receptor specificity. It has been shown to be effective for psoriasis treatment. However, its topical application is limited by its irritation.

Studies have shown that combination with other lines may optimize the efficacy as well as minimize the local irritation due to TAZ.

Betamethasone valerate (BV) is a high-potency, synthetic corticosteroid which acts on the intracellular glucocorticoid receptor.

It also binds to membrane-bound receptors, enhancing its action. BV suppresses the production of inflammatory cytokines and reduces keratinocyte hyperproliferation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Psoriasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

group of patients with psoriasis vulgaris

in each patient lesions will be divided into 3 groups; Group 1: treated with Excimer laser alone(1-2 sessions/ week for 12 sessions according to induration protocol\*).

Group 2: treated with Excimer laser combined with topical tazarotene gel 0.1% Group3: treated with Excimer laser combined with topical betamethasone valerate ointment 0.1%

Group Type EXPERIMENTAL

308nm Excimer laser

Intervention Type DEVICE

Excimer laser will be (1-2 sessions/ week for 12 sessions according to induration protocol)

Tazarotene Topical Gel

Intervention Type DRUG

Tazarotene gel 0.1%(finger tip unit of the gel) will be applied once daily for weeks

Betamethasone Valerate

Intervention Type DRUG

.Betamethasone valerate ointment 0.1% will be applied twice daily for 12 weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

308nm Excimer laser

Excimer laser will be (1-2 sessions/ week for 12 sessions according to induration protocol)

Intervention Type DEVICE

Tazarotene Topical Gel

Tazarotene gel 0.1%(finger tip unit of the gel) will be applied once daily for weeks

Intervention Type DRUG

Betamethasone Valerate

.Betamethasone valerate ointment 0.1% will be applied twice daily for 12 weeks.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age: ≥18 years.
2. Pattern: Patients with chronic plaque psoriasis not exceeding 10% of the body surface area.

Exclusion Criteria

1. History of retinoid use either topical or systemic in the previous 16 weeks, phototherapy or topical psoriasis treatment within the last 4 weeks.
2. Allergy to any ingredients of tretinoin or betamethasone drugs.
3. Renal, hepatic disease, cardiovascular , Immunosuppressive therapy, endocrine and blood disease or mental illness.
4. Pregnancy, breast-feeding or women planning to become pregnant within 3 months.
5. Psoriasis exceeding 10% of body surface area or other severe types of psoriasis requiring systemic treatment.
6. Patients with other diseases and requiring treatment that would affect the study

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No